US FDA Exclusivity Battles Continue: Alvogen and Sandoz Challenge Buprenorphine, Aubagio Awards

 
• By Brenda Sandburg

Alvogen contends Teva forfeited 180-day exclusivity with its settlement, while Sandoz claims Sanofi’s MS drug Aubagio isn’t an NCE because it is an active metabolite.

Exclusive full
FDA is sued over drug marketing exclusivity awards • Source: Shutterstock

More from US FDA

More from Agency Leadership